Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03246971 · ClinicalTrials.gov registry record · Phase 2

Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain

A Phase 2 study of Acute Pain and Bunion, sponsored by iX Biopharma.

Completed
Registry status
Phase 2
Development phase
125
Enrollment target
1
Study location

NCT03246971 is a Phase 2 study of Acute Pain and Bunion that has completed, run by iX Biopharma. The registered enrollment target is 125 participants, below the 266-participant average among 50 other Acute Pain trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03246971, a Phase 2 study of Acute Pain and Bunion, has completed, sponsored by iX Biopharma.

COMPLETED
Registry status
Phase 2
Development phase
125 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the safety and effectiveness of Wafermine™ for post-bunionectomy or post-abdominoplasty pain over a 24 hours period. For subjects undergoing bunionectomy, 2 out of 3 subjects will receive Wafermine™ and 1 out of 3 subjects will receive placebo. For subjects undergoing abdominoplasty, 3 out of 4 subjects will receive Wafermine™ and 1 out of 4 subjects will receive placebo.

Interventions

  • DRUG Placebos
  • DRUG Wafermine™ 50 mg
  • DRUG Wafermine™ 75 mg
  • DRUG Wafermine™ 25 mg

Study Locations (1)

California

  • Lotus Clinical Research - Pasadena

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2017-08-24
Est. Completion 2018-07-17
Phase Phase 2

Sponsor

iX Biopharma

3 total trials

What the Registry Record Tells You About NCT03246971

The ClinicalTrials.gov registry entry for NCT03246971 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 266-participant average among 50 other Acute Pain trials with a reported enrollment target (53% lower). The listed sponsor is iX Biopharma, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acute Pain appearing as the primary indexed condition, and to 4 interventions - of which Placebos is the first listed.

NCT03246971 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03246971 about?

NCT03246971 is a clinical study titled "Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain". This study evaluates the safety and effectiveness of Wafermine™ for post-bunionectomy or post-abdominoplasty pain over a 24 hours period. For subjects undergoing bunionectomy, 2 out of 3 subjects will receive Wafermine™ and 1 out of 3 subjects will receive placebo. For subjects undergoing abdominopl...

What is the current status of trial NCT03246971?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2017-08-24. Estimated completion is 2018-07-17.

What conditions does trial NCT03246971 study?

This clinical trial studies the following conditions: Acute Pain, Bunion, Abdominoplasty.

What interventions are being tested in trial NCT03246971?

The interventions under investigation include: Placebos (DRUG), Wafermine™ 50 mg (DRUG), Wafermine™ 75 mg (DRUG), Wafermine™ 25 mg (DRUG).

Who is sponsoring clinical trial NCT03246971?

This trial is sponsored by iX Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03246971 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.